Revenue Summary of Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.'s latest annual revenue in 2022 was 62.83 Million USD , up 18.78% from previous year.
Sorrento Therapeutics, Inc.'s latest quarterly revenue in 2023 Q2 was 15.02 Million USD , down -7.54% from previous quarter.
Sorrento Therapeutics, Inc. reported a annual revenue of 52.9 Million USD in annual revenue 2021, up 32.31% from previous year.
Sorrento Therapeutics, Inc. reported a annual revenue of 39.98 Million USD in annual revenue 2020, up 27.21% from previous year.
Sorrento Therapeutics, Inc. reported a quarterly revenue of 15.02 Million USD for 2023 Q2, down -7.54% from previous quarter.
Sorrento Therapeutics, Inc. reported a quarterly revenue of 15.59 Million USD for 2022 Q4, down -10.38% from previous quarter.

Annual Revenue Chart of Sorrento Therapeutics, Inc. (2022 - 2003)

Historical Annual Revenue of Sorrento Therapeutics, Inc. (2022 - 2003)

Year	Revenue	Revenue Growth
2022	62.83 Million USD	18.78%
2021	52.9 Million USD	32.31%
2020	39.98 Million USD	27.21%
2019	31.43 Million USD	48.31%
2018	21.19 Million USD	-86.04%
2017	151.85 Million USD	1762.81%
2016	8.15 Million USD	77.6%
2015	4.59 Million USD	20.0%
2014	3.82 Million USD	731.25%
2013	460.14 Thousand USD	-21.18%
2012	583.77 Thousand USD	10.32%
2011	529.18 Thousand USD	-22.47%
2010	682.56 Thousand USD	12509.79%
2009	5413.00 USD	0.0%
2008	- USD	0.0%
2007	- USD	0.0%
2006	- USD	0.0%
2005	- USD	0.0%
2004	- USD	0.0%
2003	- USD	0.0%

Year	Revenue	Revenue Growth
2023 Q1	16.25 Million USD	4.21%
2023 Q2	15.02 Million USD	-7.54%
2022 Q4	15.59 Million USD	-10.38%
2022 Q3	17.4 Million USD	51.82%
2022 FY	62.83 Million USD	18.78%
2022 Q2	11.46 Million USD	-37.66%
2022 Q1	18.38 Million USD	40.6%
2021 Q1	14.25 Million USD	23.9%
2021 Q2	13.51 Million USD	-5.22%
2021 Q3	12.06 Million USD	-10.72%
2021 Q4	13.07 Million USD	8.41%
2021 FY	52.9 Million USD	32.31%
2020 Q3	11.75 Million USD	30.49%
2020 FY	39.98 Million USD	27.21%
2020 Q2	9 Million USD	16.66%
2020 Q1	7.72 Million USD	-40.76%
2020 Q4	11.5 Million USD	-2.11%
2019 Q2	6.47 Million USD	5.44%
2019 Q4	13.03 Million USD	125.58%
2019 FY	31.43 Million USD	48.31%
2019 Q1	6.14 Million USD	-11.34%
2019 Q3	5.77 Million USD	-10.79%
2018 Q2	3.91 Million USD	-37.35%
2018 Q4	6.92 Million USD	68.79%
2018 FY	21.19 Million USD	-86.04%
2018 Q1	6.24 Million USD	-69.39%
2018 Q3	4.1 Million USD	4.91%
2017 Q3	121.91 Million USD	2513.29%
2017 Q1	4.87 Million USD	21.27%
2017 FY	151.85 Million USD	1762.81%
2017 Q4	20.4 Million USD	-83.26%
2017 Q2	4.66 Million USD	-4.29%
2016 FY	8.15 Million USD	77.6%
2016 Q2	902 Thousand USD	-8.7%
2016 Q1	988 Thousand USD	-26.1%
2016 Q3	2.24 Million USD	148.67%
2016 Q4	4.01 Million USD	79.18%
2015 Q2	1.17 Million USD	20.06%
2015 FY	4.59 Million USD	20.0%
2015 Q3	1.1 Million USD	-5.97%
2015 Q4	1.33 Million USD	21.21%
2015 Q1	977 Thousand USD	22.43%
2014 Q1	976 Thousand USD	869.24%
2014 FY	3.82 Million USD	731.25%
2014 Q3	1.27 Million USD	64.65%
2014 Q2	775 Thousand USD	-20.59%
2014 Q4	798 Thousand USD	-37.46%
2013 Q3	83.79 Thousand USD	-40.82%
2013 FY	460.14 Thousand USD	-21.18%
2013 Q1	134.06 Thousand USD	9.9%
2013 Q4	100.69 Thousand USD	20.18%
2013 Q2	141.59 Thousand USD	5.62%
2012 Q3	134.5 Thousand USD	-38.05%
2012 FY	583.77 Thousand USD	10.32%
2012 Q2	217.13 Thousand USD	97.13%
2012 Q1	110.14 Thousand USD	-13.88%
2012 Q4	121.98 Thousand USD	-9.31%
2011 Q1	235.36 Thousand USD	-54.01%
2011 Q3	91.75 Thousand USD	23.73%
2011 FY	529.18 Thousand USD	-22.47%
2011 Q2	74.15 Thousand USD	-68.49%
2011 Q4	127.9 Thousand USD	39.4%
2010 Q4	511.77 Thousand USD	347.62%
2010 Q1	- USD	-100.0%
2010 Q2	56.46 Thousand USD	0.0%
2010 Q3	114.33 Thousand USD	102.48%
2010 FY	682.56 Thousand USD	12509.79%
2009 Q3	- USD	0.0%
2009 Q1	- USD	0.0%
2009 FY	5413.00 USD	0.0%
2009 Q4	5413.00 USD	0.0%
2009 Q2	- USD	0.0%
2008 Q3	- USD	0.0%
2008 Q4	- USD	0.0%
2008 Q2	- USD	0.0%
2008 Q1	- USD	0.0%
2008 FY	- USD	0.0%
2007 Q3	- USD	0.0%
2007 Q1	- USD	0.0%
2007 FY	- USD	0.0%
2007 Q4	- USD	0.0%
2007 Q2	- USD	0.0%
2006 FY	- USD	0.0%
2006 Q1	- USD	0.0%
2005 Q3	- USD	0.0%
2005 Q1	- USD	0.0%
2005 FY	- USD	0.0%
2005 Q4	- USD	0.0%
2005 Q2	- USD	0.0%
2004 FY	- USD	0.0%
2004 Q2	- USD	0.0%
2004 Q1	- USD	0.0%
2004 Q3	- USD	0.0%
2004 Q4	- USD	0.0%
2003 FY	- USD	0.0%

Peer Revenue Comparison of Sorrento Therapeutics, Inc.

Name	Revenue	Revenue Difference
America Great Health	204.3 Thousand USD	-30656.994%
Ampio Pharmaceuticals, Inc.	- USD	-Infinity%
Aridis Pharmaceuticals, Inc.	- USD	-Infinity%
Biora Therapeutics, Inc.	4000.00 USD	-1570875.0%
Bio-Path Holdings, Inc.	- USD	-Infinity%
Better Therapeutics, Inc.	- USD	-Infinity%
Calithera Biosciences, Inc.	- USD	-Infinity%
Comera Life Sciences Holdings, Inc.	633.1 Thousand USD	-9825.573%
Gene Biotherapeutics, Inc.	- USD	-Infinity%
eFFECTOR Therapeutics, Inc.	- USD	-Infinity%
Eloxx Pharmaceuticals, Inc.	- USD	-Infinity%
Evelo Biosciences, Inc.	- USD	-Infinity%
Evolutionary Genomics, Inc.	- USD	-Infinity%
Finch Therapeutics Group, Inc.	107 Thousand USD	-58628.037%
Galera Therapeutics, Inc.	- USD	-Infinity%
Innovation1 Biotech Inc.	- USD	-Infinity%
Kiromic BioPharma, Inc.	- USD	-Infinity%
Molecular Templates, Inc.	57.3 Million USD	-9.655%
Navidea Biopharmaceuticals, Inc.	65.65 Thousand USD	-95615.287%
NexImmune, Inc.	- USD	-Infinity%
Orgenesis Inc.	530 Thousand USD	-11756.415%
Panbela Therapeutics, Inc.	- USD	-Infinity%
Point of Care Nano-Technology, Inc.	- USD	-Infinity%
PaxMedica, Inc. Common Stock	- USD	-Infinity%
Scopus BioPharma Inc.	- USD	-Infinity%
Statera Biopharma, Inc.	- USD	-Infinity%
TRACON Pharmaceuticals, Inc.	12.04 Million USD	-421.702%
Trevena, Inc.	3.12 Million USD	-1910.848%
Vaxxinity, Inc.	- USD	-Infinity%
Vaccinex, Inc.	570 Thousand USD	-10924.386%
Vicapsys Life Sciences, Inc.	- USD	-Infinity%
Viracta Therapeutics, Inc.	- USD	-Infinity%
ZIVO Bioscience, Inc.	27.65 Thousand USD	-227165.823%

Global Stocks Search

Sorrento Therapeutics, Inc. (SRNE)

Revenue Summary of Sorrento Therapeutics, Inc.

Annual Revenue Chart of Sorrento Therapeutics, Inc. (2022 - 2003)

Historical Annual Revenue of Sorrento Therapeutics, Inc. (2022 - 2003)

Peer Revenue Comparison of Sorrento Therapeutics, Inc.